medigraphic.com
ISSN 2448-8909 (Print)

2014, Number 3

<< Back Next >>

Med Crit 2014; 28 (3)

Refractory status epilepticus in the intensive care environment

Mata VJF

Language: Spanish
References: 93
Page: 175-186
PDF size: 288.16 Kb.


ABSTRACT

There are differences between the definitions and these vary between each other depending on the authors, the term status epilepticus (SE) generally refers to the emergence of a crisis that may well be unique and relentless with a duration of 5-10 minutes or a group of frequent clinical seizures without a return of consciousness.


REFERENCES

  1. Aminoff MJ, Simon RP. Status epilepticus. Causes, clinical features and consequences in 98 patients. Am J Med. 1980;69:657.

  2. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America’s Working Group on Status Epilepticus. JAMA. 1993;270:854.

  3. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998;338:970.

  4. DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995;12:316.

  5. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59:205.

  6. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2005;76:534.

  7. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35:27.

  8. Boyd JG, Taylor S, Rossiter JP, et al. New-onset refractory status epilepticus with restricted DWI and neuronophagia in the pulvinar. Neurology. 2010;74:1003.

  9. Wilder-Smith EP, Lim EC, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singapore. 2005;34:417.

  10. Costello DJ, Kilbride RD, Cole AJ. Cryptogenic new onset refractory status epilepticus (NORSE) in adults-infectious or not? J Neurol Sci. 2009;277:26.

  11. Rathakrishnan R, Wilder-Smith EP. New onset refractory status epilepticus (NORSE). J Neurol Sci. 2009;284:220; author reply 220.

  12. Bausell R, Svoronos A, Lennihan L, Hirsch LJ. Recovery after severe refractory status epilepticus and 4 months of coma. Neurology. 2011;77:1494.

  13. Logroscino G, Hesdorffer DC, Cascino G, et al. Short-term mortality after a first episode of status epilepticus. Epilepsia. 1997;38:1344.

  14. Hauser WA. Status epilepticus: epidemiologic considerations. Neurology. 1990;40:9.

  15. Chin RF, Neville BG, Scott RC. A systematic review of the epidemiology of status epilepticus. Eur J Neurol. 2004;11:800.

  16. Koubeissi M, Alshekhlee A. In-hospital mortality of generalized convulsive status epilepticus: a large US sample. Neurology. 2007;69:886.

  17. Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980’s. Neurology. 1993;43:483.

  18. Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia. 2001;42:380.

  19. Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of etiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry. 2006;77:611.

  20. Canouï-Poitrine F, Bastuji-Garin S, Alonso E, et al. Risk and prognostic factors of status epilepticus in the elderly: a case-control study. Epilepsia. 2011;52:1849.

  21. Shorvon S. Prognosis and outcome of status epilepticus. In: Shorvon S. Status epilepticus: its clinical features and treatment in children and adults. Cambridge: Cambridge University Press; 1999: p. 293.

  22. Claassen J, Lokin JK, Fitzsimmons BF, et al. Predictors of functional disability and mortality after status epilepticus. Neurology. 2002;58:139.

  23. Manno EM, Pfeifer EA, Cascino GD, et al. Cardiac pathology in status epilepticus. Ann Neurol. 2005;58:954.

  24. Simon RP, Aminoff MJ, Benowitz NL. Changes in plasma catecholamines after tonic-clonic seizures. Neurology. 1984;34:255.

  25. Fountain NB, Lothman EW. Pathophysiology of status epilepticus. J Clin Neurophysiol. 1995;12:326.

  26. Payne TA, Bleck TP. Status epilepticus. Crit Care Clin. 1997;13:17.

  27. Chapman MG, Smith M, Hirsch NP. Status epilepticus. Anaesthesia. 2001;56:648.

  28. Donaire A, Carreno M, Gómez B, et al. Cortical laminar necrosis related to prolonged focal status epilepticus. J Neurol Neurosurg Psychiatry. 2006;77:104.

  29. Parmar H, Lim SH, Tan NC, Lim CC. Acute symptomatic seizures and hippocampus damage: DWI and MRS findings. Neurology. 2006;66:1732.

  30. Scholtes FB, Renier WO, Meinardi H. Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia. 1994;35:1104.

  31. Cooper AD, Britton JW, Rabinstein AA. Functional and cognitive outcome in prolonged refractory status epilepticus. Arch Neurol. 2009;66:1505.

  32. Legriel S, Azoulay E, Resche-Rigon M, et al. Functional outcome after convulsive status epilepticus. Crit Care Med. 2010;38:2295.

  33. Hesdorffer DC, Logroscino G, Cascino GD, Hauser WA. Recurrence of afebrile status epilepticus in a population-based study in Rochester, Minnesota. Neurology. 2007;69:73.

  34. Westmoreland BF. Epileptiform electroencephalographic patterns. Mayo Clin Proc. 1996;71:501.

  35. Reiher J, Rivest J, Grand’Maison F, Leduc CP. Periodic lateralized epileptiform discharges with transitional rhythmic discharges: association with seizures. Electroencephalogr Clin Neurophysiol. 1991;78:12.

  36. Tatum WO, Alavi A, Stecker MM. Technetium-99m-HMPAO SPECT in partial status epilepticus. J Nucl Med. 1994;35:1087.

  37. Henry TR, Drury I, Brunberg JA, et al. Focal cerebral magnetic resonance changes associated with partial status epilepticus. Epilepsia. 1994;35:35.

  38. Chu K, Kang DW, Kim JY, et al. Diffusion-weighted magnetic resonance imaging in nonconvulsive status epilepticus. Arch Neurol. 2001;58:993.

  39. Briellmann RS, Wellard RM, Jackson GD. Seizure-associated abnormalities in epilepsy: evidence from MR imaging. Epilepsia. 2005;46:760.

  40. Privitera M, Hoffman M, Moore JL, Jester D. EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness. Epilepsy Res. 1994;18:155.

  41. Chen DK, So YT, Fisher RS, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2005;65:668.

  42. Holtkamp M, Othman J, Buchheim K, Meierkord H. Diagnosis of psychogenic nonepileptic status epilepticus in the emergency setting. Neurology. 2006;66:1727.

  43. Walker MC, Smith SJ, Shorvon SD. The intensive care treatment of convulsive status epilepticus in the UK. Results of a national survey and recommendations. Anaesthesia. 1995;50:130.

  44. Treiman DM. Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia. 1989;30(Suppl. 2):S4.

  45. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med. 1992;20:483.

  46. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339:792.

  47. Prensky AL, Raff MC, Moore MJ, Schwab RS. Intravenous diazepam in the treatment of prolonged seizure activity. N Engl J Med. 1967;276:779.

  48. Walker M. Status epilepticus: an evidence based guide. BMJ. 2005;331:673.

  49. Fakhoury T, Chumley A, Bensalem-Owen M. Effectiveness of diazepam rectal gel in adults with acute repetitive seizures and prolonged seizures: a single-center experience. Epilepsy Behav. 2007;11:357.

  50. Prasad K, Al-Roomi K, Krishnan PR, Sequeira R. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2005;CD003723.

  51. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5:253.

  52. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366:205.

  53. de Haan GJ, van der Geest P, Doelman G, et al. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia. 2010;51:478.

  54. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591.

  55. Wills B, Erickson T. Chemically induced seizures. Clin Lab Med. 2006;26:185.

  56. Paloucek FP, Rodvold KA. Evaluation of theophylline overdoses and toxicities. Ann Emerg Med. 1988;17:135.

  57. Blake KV, Massey KL, Hendeles L, et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med. 1988;17:1024.

  58. Coplin WM, Rhoney DH, Rebuck JA, et al. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Neurol Res. 2002;24:842.

  59. Swadron SP, Rudis MI, Azimian K, et al. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med. 2004;11:244.

  60. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol. 1989;25:213.

  61. Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology. 1988;38:202.

  62. Yaffe K, Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology. 1993;43:895.

  63. Kress HG, Segmüller R. Intravenous anesthetics and human neutrophil granulocyte motility in vitro. Anaesthesist. 1987;36:356.

  64. Forbes AR, Gamsu G. Depression of lung mucociliary dlearance by thiopental and halothane. Anesth Analg. 1979;58:387.

  65. Parviainen I, Uusaro A, Kälviäinen R, et al. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002;59:1249.

  66. Rossetti AO, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia. 2004;45:757.

  67. Stecker MM, Kramer TH, Raps EC, et al. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia. 1998;39:18.

  68. Zarovnaya EL, Jobst BC, Harris BT. Propofol-associated fatal myocardial failure and rhabdomyolysis in an adult with status epilepticus. Epilepsia. 2007;48:1002.

  69. Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology. 2000;55:722.

  70. Ramsay RE, Cantrell D, Collins SD, et al. Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy. Epilepsy Res. 2003;52:189.

  71. Wheless JW, Vazquez BR, Kanner AM, et al. Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology. 2004;63:1507.

  72. Limdi NA, Shimpi AV, Faught E, et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology. 2005;64:353.

  73. Limdi NA, Knowlton RK, Cofield SS, et al. Safety of rapid intravenous loading of valproate. Epilepsia. 2007;48:478.

  74. Hodges BM, Mazur JE. Intravenous valproate in status epilepticus. Ann Pharmacother. 2001;35:1465.

  75. Yu KT, Mills S, Thompson N, Cunanan C. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia. 2003;44:724.

  76. Misra UK, Kalita J, Patel R. Sodium valproate versus phenytoin in status epilepticus: a pilot study. Neurology. 2006;67:340.

  77. Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16:527.

  78. Rossetti AO, Bromfield EB. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology. 2005;65:500.

  79. Towne AR, Garnett LK, Waterhouse EJ, et al. The use of topiramate in refractory status epilepticus. Neurology. 2003;60:332.

  80. Bensalem MK, Fakhoury TA. Topiramate and status epilepticus: report of three cases. Epilepsy Behav. 2003;4:757.

  81. Reuber M, Evans J, Bamford JM. Topiramate in drug-resistant complex partial status epilepticus. Eur J Neurol. 2002;9:111.

  82. Knake S, Gruener J, Hattemer K, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2008;79:588.

  83. Möddel G, Bunten S, Dobis C, et al. Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2009;80:689.

  84. Eue S, Grumbt M, Müller M, Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav. 2009;15:467.

  85. Álvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011;52:1292.

  86. Höfler J, Unterberger I, Dobesberger J, et al. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52:e148.

  87. Marik PE, Varon J. The management of status epilepticus. Chest. 2004;126:582.

  88. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43:146.

  89. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol. 2005;62:1698.

  90. Holtkamp M, Othman J, Buchheim K, et al. A “malignant” variant of status epilepticus. Arch Neurol. 2005;62:1428.

  91. Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345:631.

  92. INEGI: comunicado 087/06

  93. Comunicación verbal con el Dr. Horacio Sentíes. Presidente del Capítulo Mexicano de la Liga contra la Epilepsia.




2020     |     www.medigraphic.com